A randomized, double-blind, placebo-controlled, parallel-group, 6-week clinical study to assess the effect of inhaled aclidinium bromide (LAS34273) 200 [micrograms] on exercise endurance and lung hyperinflation in patients with moderate to severe COPD [chronic obstructive pulmonary disease].

Trial Profile

A randomized, double-blind, placebo-controlled, parallel-group, 6-week clinical study to assess the effect of inhaled aclidinium bromide (LAS34273) 200 [micrograms] on exercise endurance and lung hyperinflation in patients with moderate to severe COPD [chronic obstructive pulmonary disease].

Completed
Phase of Trial: Phase III

Latest Information Update: 18 Nov 2016

At a glance

  • Drugs Aclidinium bromide (Primary)
  • Indications Chronic obstructive pulmonary disease
  • Focus Pharmacodynamics; Registrational
  • Most Recent Events

    • 22 Sep 2010 Results presented at the 20th Annual Congress of the European Respiratory Society.
    • 18 May 2010 Results published in 106th International Conference of the American Thoracic Society.
    • 09 Sep 2009 Results from this trial will be used in support of a Marketing Authorisation Application with the European Medicines Agency in early 2010 according to an Almirall media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top